Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Cérebro gigante, game educativo e blecaute marcam o Dia Mundial do AVC
  • Brazil - Português

Ações em São Paulo (SP) e no Rio de Janeiro (RJ) ressaltam a importância do atendimento rápido nos casos de acidente vascular cerebral, principal causa de incapacidade funcional no mundo¹


News provided by

Boehringer Ingelheim

Oct 30, 2018, 15:27 ET

Share this article

Share toX

Share this article

Share toX

SÃO PAULO, 30 de outubro de 2018 /PRNewswire/ -- Nesta segunda-feira (29/10), em alusão ao Dia Mundial do AVC, a estação Clínicas do metrô, em São Paulo (SP), foi palco da ação "Que doença é esta?". No local, o público foi desafiado, em apenas um minuto, a identificar o AVC a partir de dez dicas sobre a doença. O objetivo foi trazer à tona o impacto da enfermidade, principalmente no que se refere a possíveis sequelas graves, caso o indivíduo não receba um atendimento emergencial adequado.

Continue Reading
Ação na estação Clínicas, em São Paulo (SP), teve interação com o público em alerta ao AVC. Crédito da foto: Junior Rosa
Ação na estação Clínicas, em São Paulo (SP), teve interação com o público em alerta ao AVC. Crédito da foto: Junior Rosa
Cérebro gigante na Central do Brasil, no Rio de Janeiro (RJ), alerta para o AVC. Crédito da foto: Du Machado
Cérebro gigante na Central do Brasil, no Rio de Janeiro (RJ), alerta para o AVC. Crédito da foto: Du Machado
Arcos da Lapa, no Rio de Janeiro (RJ) tiveram a luz apagada e a projeção da campanha “A Vida Conta - Cada minuto faz diferença”.
Arcos da Lapa, no Rio de Janeiro (RJ) tiveram a luz apagada e a projeção da campanha “A Vida Conta - Cada minuto faz diferença”.

No Rio de Janeiro (RJ), um cérebro gigante exposto na Central do Brasil alertou para a necessidade de urgência exigida pela doença.  

À noite, às luzes dos Arcos da Lapa, um dos símbolos da Capital Fluminense, foram apagadas em referência à rápida perda de neurônios que os pacientes acometidos pela doença sofrem. Em seguida, o monumento recebeu uma projeção especial em alerta à campanha "A Vida Conta – Cada minuto faz diferença", da Rede Brasil AVC em parceria com a Sociedade Brasileira de Doenças Cerebrovasculares.

As três iniciativas fazem parte da campanha "A Vida Conta – Cada minuto faz diferença", que tem o apoio da Boehringer Ingelheim e visa alertar o grande potencial de comprometimento do AVC.  "A ação com o game serviu de desafio e, ao mesmo tempo, informa e educa as pessoas a saberem que o AVC é uma emergência médica em que a rapidez no atendimento é fundamental. No caso do AVC isquêmico, o que mais acomete a população, em cerca de 85% das vezes2, um paciente não tratado perde, aproximadamente, 1,9 milhão de neurônios a cada minuto3. Quanto mais tempo sem atendimento, maior a chance de sequelas graves, como dificuldades de movimentação, linguagem, comprometimentos visuais, de memória e até mesmo comportamentais, de acordo com a área do cérebro afetada. Ou seja, tempo é cérebro", afirma Dra. Sheila Martins, neurologista e presidente da Rede Brasil AVC. 

"Noventa por cento dos casos podem ser evitados com o controle dos fatores de risco, tais como pressão alta, diabetes, colesterol elevado, arritmias cardíacas, tabagismo, obesidade, sedentarismo e estresse. Além disso, é importante ressaltar que o AVC é uma doença tratável. Hoje, no caso do isquêmico, existe um medicamento injetável altamente eficaz. Estudos mostram que esse medicamento, chamado de trombolítico, quando usado no paciente, em até 4h30min após o início dos sintomas, pode desobstruir o vaso entupido e aumentar em 30% as chances desse indivíduo ficar sem sequelas do AVC", explica o Dr. Octavio Pontes Neto, neurologista e presidente da Sociedade Brasileira de Doenças Cerebrovasculares.   

Sobre a Campanha "A Vida Conta"

A campanha "A Vida Conta – Cada minuto faz diferença", é uma iniciativa da Rede Brasil AVC em parceria com a Sociedade Brasileira de Doenças Cerebrovasculares, com o apoio da Boehringer Ingelheim. Siga a campanha na Fanpage da Rede Brasil AVC: https://www.facebook.com/CampanhaAVC

Sobre a Rede Brasil AVC: https://pt-br.facebook.com/CampanhaAVC/

Sobre a Sociedade Brasileira de Doenças Cerebrovasculares: http://sbdcv.org.br/medica_index.asp

Sobre a Boehringer Ingelheim: www.boehringer-ingelheim.com.br e www.facebook.com/BoehringerIngelheimBrasil

Referências:

1.       Feigin et al 2015-2016.

2.       Sociedade Brasileira de Doenças Cerebrocardiovasculares. Acidente Vascular Cerebral. Disponível em: http://sbdcv.org.br/publica_avc.asp . Acesso em outubro de 2018.

3.       Saver J. Stroke 2006;37:263-266

Tino Comunicação
Vinicius Volpi – [email protected]
11-5049-1759/11-97492-8040

(Foto 1:  https://mma.prnewswire.com/media/777198/Boehringer_Ingelheim.jpg)

(Foto 2: https://mma.prnewswire.com/media/777197/Boehringer_Ingelheim.jpg)

(Foto 3: https://mma.prnewswire.com/media/777196/Boehringer_Ingelheim.jpg)

FONTE Boehringer Ingelheim

Related Links

http://www.boehringer-ingelheim.com.br

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Also from this source

FDA grants HERNEXEOS® Breakthrough Therapy Designation for first line use in HER2 (ERBB2)-mutant advanced NSCLC

FDA grants HERNEXEOS® Breakthrough Therapy Designation for first line use in HER2 (ERBB2)-mutant advanced NSCLC

Boehringer Ingelheim today announced HERNEXEOS® (zongertinib tablets) has been granted Breakthrough Therapy Designation by the U.S. Food and Drug...

Boehringer Ingelheim Showcases Bold Vision for the Future of Cancer Care at ASCO 2025

Boehringer Ingelheim Showcases Bold Vision for the Future of Cancer Care at ASCO 2025

oehringer Ingelheim will present the latest data in its robust oncology pipeline at the 2025 American Society of Clinical Oncology (ASCO) Annual...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Mental Health

Mental Health

Electronic Gaming

Electronic Gaming

News Releases in Similar Topics

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.